Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company’s lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.
NASDAQ ADRO (Common Stock) 0.211.53%)August 30, 20164:00 p.m. ET
August 04, 2016 Aduro Biotech to Present at Canaccord Genuity Growth Conference
August 03, 2016 Aduro Biotech Reports Second Quarter 2016 Financial Results
Events & Presentations
|Data Provided by Thomson Reuters|